Island Pharmaceuticals Ltd has released a press release.
Non-binding term sheet signed with BioCryst
Filed with ASX ·
6ix hasn’t read this filing yet.
Island Pharmaceuticals Ltd on 6ix
Earlier from Island Pharmaceuticals
- Investor Presentation
- New data leads to proposed ISLA-101 Phase 2 efficiencies
- Grant funding to directly support Phase 2a trial
- Investor Presentation - Asia Bio Partnering
- Positive data from ISLA-101 Single Ascending Dose study
Later from Island Pharmaceuticals
- ISLA-101 Phase 2a/b clinical trial progresses
- Binding LOI for proposed acquisition of Galidesivir
- Phase 2a PROTECT clinical trial dosed & Investor webinar
- Island completes $3.5m Placement
- Clinical trial progress update
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals